ES2963665T3 - Régimen de dosificación de 21 días para proteínas de fusión que comprenden factor ix y albúmina humana para el tratamiento profiláctico de la hemofilia y procedimientos para ello - Google Patents

Régimen de dosificación de 21 días para proteínas de fusión que comprenden factor ix y albúmina humana para el tratamiento profiláctico de la hemofilia y procedimientos para ello Download PDF

Info

Publication number
ES2963665T3
ES2963665T3 ES18736860T ES18736860T ES2963665T3 ES 2963665 T3 ES2963665 T3 ES 2963665T3 ES 18736860 T ES18736860 T ES 18736860T ES 18736860 T ES18736860 T ES 18736860T ES 2963665 T3 ES2963665 T3 ES 2963665T3
Authority
ES
Spain
Prior art keywords
fusion protein
fix
factor
coagulation
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18736860T
Other languages
English (en)
Spanish (es)
Inventor
Yanyan Li
Debra Bensen-Kennedy
Iris Jacobs
Christine Voigt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring Lengnau AG
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Application granted granted Critical
Publication of ES2963665T3 publication Critical patent/ES2963665T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ES18736860T 2017-06-29 2018-06-29 Régimen de dosificación de 21 días para proteínas de fusión que comprenden factor ix y albúmina humana para el tratamiento profiláctico de la hemofilia y procedimientos para ello Active ES2963665T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762526377P 2017-06-29 2017-06-29
PCT/EP2018/067523 WO2019002532A1 (en) 2017-06-29 2018-06-29 21-DAY FUSION PROTEIN DRAFTING COMPRISING IX FACTOR AND HUMAN ALBUMIN FOR THE PROPHYLACTIC TREATMENT OF HEMOPHILIA AND ASSOCIATED METHODS

Publications (1)

Publication Number Publication Date
ES2963665T3 true ES2963665T3 (es) 2024-04-01

Family

ID=62815032

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18736860T Active ES2963665T3 (es) 2017-06-29 2018-06-29 Régimen de dosificación de 21 días para proteínas de fusión que comprenden factor ix y albúmina humana para el tratamiento profiláctico de la hemofilia y procedimientos para ello

Country Status (15)

Country Link
US (1) US20200115436A1 (enExample)
EP (1) EP3645034B1 (enExample)
JP (1) JP2020525498A (enExample)
KR (1) KR102597725B1 (enExample)
CN (1) CN110799209A (enExample)
AU (1) AU2018294517B2 (enExample)
CA (1) CA3068360A1 (enExample)
DK (1) DK3645034T5 (enExample)
ES (1) ES2963665T3 (enExample)
IL (1) IL271160B2 (enExample)
MX (1) MX2019014651A (enExample)
PL (1) PL3645034T3 (enExample)
RU (1) RU2020103424A (enExample)
SG (1) SG10202111032PA (enExample)
WO (1) WO2019002532A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
CA2770609A1 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
AU2011274414B2 (en) * 2010-07-09 2016-10-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
HK1213521A1 (zh) * 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
KR20160093735A (ko) * 2013-12-23 2016-08-08 시에스엘 리미티드 혈우병의 예방학적 치료를 위한 인자 ix를 포함하는 융합 단백질 및 이의 방법
SG11201608006QA (en) * 2014-04-11 2016-10-28 Csl Ltd Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor

Also Published As

Publication number Publication date
AU2018294517A1 (en) 2020-01-30
PL3645034T3 (pl) 2024-09-02
DK3645034T5 (da) 2024-08-26
WO2019002532A1 (en) 2019-01-03
MX2019014651A (es) 2020-02-07
KR20200019749A (ko) 2020-02-24
CN110799209A (zh) 2020-02-14
IL271160B2 (en) 2025-05-01
IL271160A (en) 2020-01-30
US20200115436A1 (en) 2020-04-16
RU2020103424A (ru) 2021-07-29
DK3645034T3 (da) 2023-11-20
AU2018294517B2 (en) 2024-09-26
RU2020103424A3 (enExample) 2021-11-12
JP2020525498A (ja) 2020-08-27
EP3645034B1 (en) 2023-08-30
IL271160B1 (en) 2025-01-01
CA3068360A1 (en) 2019-01-03
KR102597725B1 (ko) 2023-11-06
SG10202111032PA (en) 2021-11-29
EP3645034A1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
ES2753638T3 (es) Variantes del Factor IX con actividad coagulante en presencia de su cofactor y su uso para el tratamiento de alteraciones hemorrágicas
ES2449224T3 (es) Administración subcutánea del Factor de coagulación VII
JP6250282B2 (ja) 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
ES2247106T3 (es) Uso de una composicion farmaceutica que comprende un factor viia y un factor xiii.
US9107902B2 (en) Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
US20160346366A1 (en) Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof
ES2963665T3 (es) Régimen de dosificación de 21 días para proteínas de fusión que comprenden factor ix y albúmina humana para el tratamiento profiláctico de la hemofilia y procedimientos para ello
ES2312374T3 (es) Composiciones medicinales de tratamiento y prevencion de enfermedades basadas en una coagulacion de la sangre anormal.
ES2832648T3 (es) Administración subcutánea del factor IX de acción prolongada en humanos
HK40027732A (en) 21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof
HK40027732B (en) 21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof
AU2015245941A1 (en) Half-life extended Factor FVIIa protein for prevention and treatment of bleeding and dosing regimens therefor
ES2354129T3 (es) Complementación de la deficiencia en factor xi mediante mutantes del factor v.